PREDICTORS OF RESPONSE TO GROWTH HORMONE TREATMENT AND FINAL HEIGHT IN MEDULLOBLASTOMA SURVIVORS

The authors investigate the growth characteristics and response to growth hormone treatment (GHT) in survivors of childhood medulloblastoma, aiming to identify factors influencing final height (FH) outcomes. Their findings indicate that a significant majority of patients experience growth retardation and GH deficiency, with early height-SDS at the start of treatment being the key predictor of FH success. The study emphasizes the importance of timely GH deficiency diagnosis and treatment while highlighting concerns regarding the long-term safety of GHT.